Clinical trials: Hepatitis C
Hepatitis C, Chronic
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis
This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis…
- Trial name
- STANDART (NCT01609049)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 57 sites in Russia, South Korea
- Volunteers
- 1,496 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Racial Difference in HCV/Host Interactions
The purpose of this study is to evaluate a group of African Americans and Caucasians with hepatitis C virus (HCV), compare their response rates to combination treatment with pegylated interferon alfa-2b and ribavirin, and…
- Trial name
- NCT00071916
- Where
- 3 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Reaching mEthadone Users Attending Community pHarmacies With HCV
Hepatitis C Virus (HCV) is a blood-borne virus that damages the liver and is a major public health threat globally. Most individuals infected with HCV are unaware of it and show no symptoms until presenting with incurable, fatal…
- Trial name
- REACH-HCV (NCT03935906)
- Testing
- Reach Pathway, Education-only Pathway
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 1,410 people
- Sponsor
- University of Dundee
Obesity, Insulin Resistance
Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C
Chronic hepatitis C (CHC) infection affects approximately 1 in 100 Canadians. Untreated, CHC has significant long-term consequences including cirrhosis, liver cancer and liver failure.
- Conditions
- Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
- Trial name
- NCT00755742
- Testing
- Lifestyle intervention
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Hepatitis C
HCV Virions Bound Proteins
The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis C virus (HCV).
- Trial name
- NCT02795403
- Testing
- blood draw of 150ml, twice
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
HCV Infection
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by…
- Trial name
- NCT00725803
- Testing
- GS-9450
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 33 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
Objectives: 1) To evaluate la proportion of hepatitic C virus (HCV)-monoinfected patients who show sustained virologic response (SVR) to treatment including direct-acting antivirals (DAAs) in the clinical practice in clinical…
- Trial name
- FPSMON201401 (NCT02333292)
- Testing
- Telaprevir, Boceprevir, Sofosbuvir
- Where
- Spain
- Volunteers
- 1,128 people
- Sponsor
- Valme University Hospital
Hepatitis C
Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
The purpose of this study is to compare the sustained virologic response at post treatment Week 12 for each cohort (BMS-790052/Pegylated-interferon alfa 2a (pegIFNα-2a)/Ribavirin (RBV) versus placebo/PegIFNα-2a/RBV).
- Trial name
- NCT01448044
- Testing
- BMS-790052 (NS5A Replication Complex Inhibitor), Pegylated-interferon alfa 2a, Ribavirin
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 152 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Ribavirin Bioavailability After Telaprevir Exposure
Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone.
- Trial name
- NCT02881034
- Testing
- Triple therapy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis C
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load.
- Trial name
- ImmunoDual (NCT02282709)
- Testing
- Daclatasvir, asunaprevir
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Foundation for Liver Research
Hepatitis B, Hepatitis C
A Study Done by a Demonstrator and Two Professors in Public Health and Community Medicine Department in Faculty of Medicine in Assiut and New Valley University to Assess Knowledge, Attitude ,and Practice of Rural Population in a Remote Governorate ( New Valley ) Towards Hepatitis B and C Viruses
This study is a research aiming to identify knowledge , attitude and practice of population in a village in a remote governorate towards viral hepatitis B and C .
- Trial name
- rural_remote (NCT06316492)
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
This multicenter, open-label, uncontrolled study will evaluate the efficacy and safety of increasing the dose of peginterferon alfa-2a (Pegasys) in participants with Genotype 1/4/5/6 CHC and an early non-response to a standard…
- Trial name
- NCT02791256
- Testing
- Ribavirin, peginterferon alfa-2a
- Where
- 21 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
HCV Infection, Liver Cirrhosis, Experimental
Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation
Evaluation of efficacy of triple therapy with pegylated interferon, ribavirin, and boceprevir in patients with genotype 1 chronic hepatitis C, who are treatment-naive, have relapsed, or are non-responders with cirrhosis and…
- Trial name
- NCT01463956
- Testing
- Boceprevir, Peg-Interferon α-2b or Peg-Interferon α-2a, Ribavirin
- Where
- 19 sites in France
- Volunteers
- 58 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Healthy Participants
A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants
The purpose of this study is to assess the relative bioavailability (the degree to which the study medication becomes available in the blood circulation) of JNJ-47910382, given as an uncoated tablet and as a suspension, after a…
- Trial name
- NCT01662661
- Testing
- JNJ-47910382 (suspension), JNJ-47910382 (tablet)
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
HIV Infection, Hepatitis C
Improving Fibrosis Outcomes With Metformin
This study will evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance receiving DAA HCV treatment.
- Trial name
- NCT02306070
- Testing
- Metformin, No metformin treatment
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Hepatitis C, Chronic
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment.
- Trial name
- NCT00724373
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 442 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C
Dendritic cells (DC) play a central role in the activation of T-cell responses and have shown to be very immunogenic in preclinical in vivo and in vitro assays.
- Trial name
- NCT02309086
- Testing
- Autologous dendritic cells transduced with Ad encoding NS3
- Volunteers
- 5 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatitis C, Transmission
Vertical Transmission of Hepatitis C Virus
Vertical HCV Transmission has been extensively studied, with a risk around 5% (range: 3 to 10%). Spontaneous viral clearance in infected children during childhood can occur, but data about this phenomenon are scarse, justifying…
- Trial name
- NCT02044042
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hopital Lariboisière
Hepatitis C, Chronic
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
- Trial name
- NCT00375661
- Testing
- interferon-alfa-2b and ribavirin
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
Hepatitis C, HCV
Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood
The objectives of the study are to determine the impact of interferon-free treatment for the hepatitis C virus (HCV) on peripheral blood immune cell phenotype and soluble immune-related proteins in blood, while controlling for…
- Conditions
- Hepatitis C, HCV, Liver Transplant
- Trial name
- NCT02718573
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Icahn School of Medicine at Mount Sinai